Konstantin Chegaev

List of Publications by Citations

Source: https://exaly.com/author-pdf/2376384/konstantin-chegaev-publications-by-citations.pdf
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

56 papers	1,037 citations	20 h-index	30 g-index
60 ext. papers	1,186 ext. citations	5.3 avg, IF	3.62 L-index

#	Paper	IF	Citations
56	Nitric oxide donor doxorubicins accumulate into Doxorubicin-resistant human colon cancer cells inducing cytotoxicity. *ACS Medicinal Chemistry Letters*, **2011**, 2, 494-7	4.3	58
55	Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug resistance. *Molecular Pharmaceutics*, **2013**, 10, 161-74	5.6	52
54	NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties. *Journal of Medicinal Chemistry*, **2007**, 50, 1449-57	8.3	52
53	Phenylsulfonylfuroxans as modulators of multidrug-resistance-associated protein-1 and P-glycoprotein. *Journal of Medicinal Chemistry*, **2010**, 53, 5467-75	8.3	49
52	Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis. *European Journal of Medicinal Chemistry*, **2016**, 123, 523-531	6.8	48
51	Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors. *Journal of Controlled Release*, **2018**, 270, 37-52	11.7	47
50	NO-donor phenols: a new class of products endowed with antioxidant and vasodilator properties. *Journal of Medicinal Chemistry*, **2006**, 49, 2886-97	8.3	43
49	Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance. *ACS Medicinal Chemistry Letters*, **2017**, 8, 361-365	4.3	35
48	H2S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance. *Journal of Medicinal Chemistry*, **2016**, 59, 4881-9	8.3	35
47	Leishmanicidal activities of novel synthetic furoxan and benzofuroxan derivatives. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 4837-47	5.9	32
46	Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma. *Cellular and Molecular Life Sciences*, **2019**, 76, 609-625	10.3	32
45	Edaravone derivatives containing NO-donor functions. *Journal of Medicinal Chemistry*, **2009**, 52, 574-8	8.3	31
44	(Nitrooxyacyloxy)methyl esters of aspirin as novel nitric oxide releasing aspirins. *Journal of Medicinal Chemistry*, **2009**, 52, 5058-68	8.3	30
43	Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity. *Journal of Medicinal Chemistry*, **2017**, 60, 8647-8660	8.3	29
42	New nitric oxide or hydrogen sulfide releasing aspirins. *Journal of Medicinal Chemistry*, **2011**, 54, 5478-84	8.3	28
41	Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells. *Molecular Pharmaceutics*, **2014**, 11, 3068-79	5.6	27
40	Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts. *Cancer Letters*, **2019**, 456, 29-39	9.9	26

39	Furazan and furoxan sulfonamides are strong carbonic anhydrase inhibitors and potential antiglaucoma agents. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 3913-21	3.4	25
38	Development of a new class of potential antiatherosclerosis agents: NO-donor antioxidants. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 5971-4	2.9	23
37	Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 967-75	3.4	21
36	New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations. *Investigational New Drugs*, **2018**, 36, 985-998	4.3	19
35	Doxorubicin-antioxidant co-drugs. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 5307-10	2.9	19
34	A nitric oxide-donor furoxan moiety improves the efficacy of edaravone against early renal dysfunction and injury evoked by ischemia/reperfusion. *Oxidative Medicine and Cellular Longevity*, **2015**, 2015, 804659	6.7	18
33	Structure-Activity Relationship Studies on Tetrahydroisoquinoline Derivatives: [4∀(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-ylmethyl)biphenyl-4-ol] (MC70) Conjugated through Flexible Alkyl Chains with Furazan Moieties Gives Rise to Potent and Selective Ligands of P-glycoprotein. *Journal of Medicinal Chemistry*, **2016**, 59, 6729-38	8.3	17
32	Multitarget drugs: Focus on the NO-donor hybrid drugs. *Pure and Applied Chemistry*, **2008**, 80, 1693-1701	2.1	17
31	Mitochondrial Delivery of Phenol Substructure Triggers Mitochondrial Depolarization and Apoptosis of Cancer Cells. *Frontiers in Pharmacology*, **2018**, 9, 580	5.6	16
30	NO-donor thiacarbocyanines as multifunctional agents for Alzheimer∀ disease. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 4688-4698	3.4	16
29	New functional glycoluril derivatives. *Mendeleev Communications*, **2001**, 11, 32-33	1.9	16
28	Novel antioxidant agents deriving from molecular combination of Vitamin C and NO-donor moieties. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 5199-206	3.4	15
27	Synthesis of 2-monofunctionalized 2,4,6,8-tetraazabicyclo[3.3.0]octane-3,7-diones. *Russian Chemical Bulletin*, **2003**, 52, 192-197	1.7	14
26	Solid lipid nanoparticles carrying lipophilic derivatives of doxorubicin: preparation, characterization, and in vitro cytotoxicity studies. *Journal of Microencapsulation*, **2016**, 33, 381-90	3.4	14
25	Structural and biological characterization of new hybrid drugs joining an HDAC inhibitor to different NO-donors. *European Journal of Medicinal Chemistry*, **2018**, 144, 612-625	6.8	13
24	NO-donor melatonin derivatives: synthesis and in vitro pharmacological characterization. *Journal of Pineal Research*, **2007**, 42, 371-85	10.4	12
23	Unsymmetrically substituted furoxans. Part 19. Methyl and phenylfuroxansulfonic acids and related sulfonamides. *Journal of Heterocyclic Chemistry*, **2009**, 46, 866-872	1.9	10
22	New tetrahydroisoquinoline-based P-glycoprotein modulators: decoration of the biphenyl core gives selective ligands. *MedChemComm*, **2018**, 9, 862-869	5	9

21	New Tetrahydroisoquinoline Derivatives Overcome Pgp Activity in Brain-Blood Barrier and Glioblastoma Multiforme in Vitro. *Molecules*, **2018**, 23,	4.8	9
20	Galactosylated Pro-Drug of Ursodeoxycholic Acid: Design, Synthesis, Characterization, and Pharmacological Effects in a Rat Model of Estrogen-Induced Cholestasis. *Molecular Pharmaceutics*, **2018**, 15, 21-30	5.6	8
19	Aceclofenac-Galactose Conjugate: Design, Synthesis, Characterization, and Pharmacological and Toxicological Evaluations. *Molecular Pharmaceutics*, **2018**, 15, 3101-3110	5.6	7
18	Discovery of phenylsulfonylfuroxan derivatives as gamma globin inducers by histone acetylation. *European Journal of Medicinal Chemistry*, **2018**, 154, 341-353	6.8	7
17	Synthesis, chiral HPLC resolution and configuration assignment of 1-phenylglyceryl trinitrate stereomers. *Chirality*, **2006**, 18, 430-6	2.1	6
16	Solid Lipid Nanoparticles Loaded with Antitumor Lipophilic Prodrugs Aimed to Glioblastoma Treatment: Preliminary Studies on Cultured Cells. *Journal of Nanoscience and Nanotechnology*, **2017**, 17, 3606-3614	1.3	5
15	New furoxan derivatives for the treatment of ocular hypertension. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 479-483	2.9	5
14	Paracetamol-Galactose Conjugate: A Novel Prodrug for an Old Analgesic Drug. *Molecular Pharmaceutics*, **2019**, 16, 4181-4189	5.6	5
13	Synthesis and Biological Evaluation of N(2) -Substituted 2,4-Diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines and Related 5-Cyano-NNO-azoxy Derivatives as Cyclin-Dependent Kinase 2 (CDK2) Inhibitors. *ChemMedChem*, **2016**, 11, 1705-8	3.7	5
12	Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs. *Bioorganic and Medicinal Chemistry*, **2012**, 20, 841-50	3.4	5
11	MRP5 nitration by NO-releasing gemcitabine encapsulated in liposomes confers sensitivity in chemoresistant pancreatic adenocarcinoma cells. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2020**, 1867, 118824	4.9	5
10	Direct introduction of cyano group on furoxan ring. *Mendeleev Communications*, **2017**, 27, 565-566	1.9	4
9	Synthesis of some novel organic nitrates and comparative in vitro study of their vasodilator profile. *Journal of Medicinal Chemistry*, **2009**, 52, 4020-5	8.3	4
8	-Dinitroalkyl Benzenes: A Novel Class of IOP-Lowering Agents for the Treatment of Ocular Hypertension. *ACS Medicinal Chemistry Letters*, **2017**, 8, 1054-1059	4.3	3
7	In vitro vascular toxicity assessment of NitDOX, a novel NO-releasing doxorubicin. *European Journal of Pharmacology*, **2020**, 880, 173164	5.3	3
6	NO release regulated by doxorubicin as the green light-harvesting antenna. *Chemical Communications*, **2020**, 56, 6332-6335	5.8	2
5	Amphiphilic NO-donor antioxidants. *ChemMedChem*, **2007**, 2, 234-40	3.7	2
4	Effects of nitric oxide donor antioxidants containing the phenol vitamin E substructure and a furoxan moiety on ischemia/reperfusion injury. *Arzneimittelforschung*, **2009**, 59, 111-6		1

List of Publications

3	Sdox, a HS releasing anthracycline, with a safer profile than doxorubicin toward vasculature.. *Vascular Pharmacology*, **2022**, 143, 106969	5.9	1
2	A Comprehensive Evaluation of Sdox, a Promising HS-Releasing Doxorubicin for the Treatment of Chemoresistant Tumors.. *Frontiers in Pharmacology*, **2022**, 13, 831791	5.6	0
1	In Vitro Assessment of NitDox Toxicity Toward Vasculature **2019**, 319-320		